Prurigo nodularis
☆ Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
References
Prurigo nodularis se yon kondisyon po ki dire lontan ki karakterize pa plizyè boul fèm ak nodil, anjeneral yo jwenn sou pati deyò bra yo ak janm yo. Bouch sa yo ka varye nan koulè soti nan kò-ton ak woz epi yo entans grate. Yo ka afekte moun nenpòt laj epi yo souvan lye ak lòt kondisyon po ki lakòz gratèl kwonik, tankou dèrmatoz atopik. Opsyon tretman yo gen ladan medikaman anti-p grate fò, dwòg ki afekte sistèm iminitè a, ak medikaman ki vize sistèm nève a. Jere prurigo nodularis anjeneral enplike terapi alontèm.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Tretman anjeneral enplike nan itilize krèm oswa piki nan estewoyid sou zòn ki afekte a. Nan ka ki pi grav oswa ki fè tèt di, tretman tankou terapi limyè oswa medikaman ki siprime sistèm iminitè a ka bezwen. Talidomid ak lenalidomid se opsyon pou ka grav, men yo ka gen efè segondè grav. Tretman ki pi nouvo yo (opioid receptor antagonists, neurokinin-1 receptor antagonists) montre pwomès nan trete prurigo nodularis ak mwens efè segondè konpare ak talidomid oswa lenalidomid.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo se yon kondisyon po ki karakterize pa grate ki dire lontan (ki dire plis pase 6 semèn) , blesi po ki gen rapò ak grafouyen, ak yon istwa nan grate souvan. Li enplike neroenflamasyon ak fibwoz nan po a.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis se yon pwoblèm po ki dire lontan ki make pa nodil grate. Nou pa konnen egzakteman sa ki lakòz li, men li sanble ke pwoblèm iminitè ak nè jwe yon wòl nan sik la grate-gratte. Kounye a, pa gen okenn tretman ki apwouve pa US FDA espesyalman pou prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Tretman - Medikaman OTC
Lave zòn blesi a ak savon pa ede ditou epi li ka vin pi mal. Odè esteroyid OTC ka ede soulaje sentòm yo, men anjeneral yo bezwen aplike pandan plizyè semèn pou amelyore. Kontinye pran antihistamin tou ede soulaje demanjezon an.
#OTC steroid ointment
#OTC antihistamine
○ Tretman
#Intralesional triamcinolone injection